TomoTherapy Incorporated (http://www.tomotherapy.com) (NASDAQ: TOMO), maker of advanced radiation therapy solutions for the treatment of cancer and other diseases, today announced that, on Friday, February 25, the company will be presented with the "Corporate Distinguished Visionary Award" by the American Cancer Society (http://www.cancer.org) . The ceremony will take place at 10 a.m. in the TomoTherapy Operations Center.
The Corporate Distinguished Visionary Award is given to companies that have portrayed exemplary public service to the American Cancer Society. This award is being presented to TomoTherapy for their efforts in the fight against cancer, and to recognize a recent $100,000 donation the company made as the exclusive sponsor of the American Cancer Society's Fall 2010 Matching Grant Challenge, a national fundraising campaign. TomoTherapy contributed $1 for every $1 donated by the general public, up to $100,000, to support the Society's efforts in fighting cancer. TomoTherapy's participation helped increase donor response by 27 percent compared to months that were not part of the Matching Grant Challenge.
"We are proud to partner with TomoTherapy and present the company with our Corporate Distinguished Visionary Award," said Jari Johnston-Allen, CEO of the American Cancer Society, Midwest Division. "TomoTherapy's support of the American Cancer Society has a direct impact on those facing cancer and our ability to help them. We are grateful for their contributions and look forward to our continued partnership in the fight against cancer."
The concepts of TomoTherapy's unique technology were developed in the early 1990s at the University of Wisconsin. A research group there recognized the inherent limitations of conventional radiation therapy machines to leverage computing, imaging and treatment delivery advances for improved sophistication in cancer care. The research group, led by Thomas "Rock" Mackie, Ph.D., and Paul Reckwerdt, set out to develop an integrated device for the delivery of CT image-guided, intensity-modulated radiation therapy (IG-IMRT). TomoTherapy Incorporated was founded in 1997 in Madison, Wis., to commercialize these concepts. In 2002, the company received FDA 510(k) clearance to market its ring gantry-based treatment system, which was first commercially used to treat a patient in July 2003. Since then the company has shipped more than 350 systems to cancer centers in 24 countries, and more than 1,500 peer-reviewed scientific papers have been published that discuss the operational and clinical advantages TomoTherapy's technology affords cancer care providers and their patients.
"TomoTherapy looks forward to accepting the Visionary Award from our partner, the American Cancer Society," said Fred Robertson, TomoTherapy's president and CEO. "It is an honor for us to be recognized for our contributions in the fight against cancer. We remain committed to our mission of enabling the best radiation therapy quality and clinical process for patients and care providers worldwide."
About the American Cancer Society The American Cancer Society combines an unyielding passion with nearly a century of experience to save lives and end suffering from cancer. As a global grassroots force of more than three million volunteers, we fight for every birthday threatened by every cancer in every community. We save lives by helping people stay well by preventing cancer or detecting it early; helping people get well by being there for them during and after a cancer diagnosis; by finding cures through investment in groundbreaking discovery; and by fighting back by rallying lawmakers to pass laws to defeat cancer and by rallying communities worldwide to join the fight. As the nation's largest non-governmental investor in cancer research, contributing more than $3.4 billion, we turn what we know about cancer into what we do. As a result, more than 11 million people in America who have had cancer and countless more who have avoided it will be celebrating birthdays this year. To learn more about us or to get help, call us any time, day or night, at 1-800-227-2345 or visit cancer.org.
About TomoTherapy Incorporated TomoTherapy Incorporated develops, markets and sells advanced radiation therapy solutions that can be used to treat a wide variety of cancers, from the most common to the most complex. The ring gantry-based TomoTherapy@ platform combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. TomoTherapy's suite of solutions include its flagship Hi-Art@ treatment system, which has been used to deliver more than three million CT-guided, helical intensity-modulated radiation therapy (IMRT) treatment fractions; the TomoHD treatment system, designed to enable cancer centers to treat a broader patient population with a single device; and the TomoMobile relocatable radiation therapy solution, designed to improve access and availability of state-of-the-art cancer care. TomoTherapy's stock is traded on the NASDAQ Global Select Market under the symbol TOMO. To learn more about TomoTherapy, please visit TomoTherapy.com (http://www.tomotherapy.com) .
5/82011 TomoTherapy Incorporated. All rights reserved. TomoTherapy, Tomo, TomoDirect, TQA, the TomoTherapy logo and Hi-Art are among trademarks, service marks or registered trademarks of TomoTherapy Incorporated in the United States and other countries.